Clearside Biomedical

Clearside Biomedical ROA

Delisted

The Return on Assets (ROA) of Clearside Biomedical (CLSD) as of Nov 20, 2026 is -136.72 %. In the previous year, Return on Assets (ROA) was -95.49 % — a change of 43.17% (lower).

ROA

-136.72 %

YoY

43.17%

Last updated:

In 2024, Clearside Biomedical's return on assets (ROA) was -136.72 %, a 43.17% increase from the -95.49 % ROA in the previous year.

The Clearside Biomedical ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2017
-145.67 USD
Jan 1, 2018
-187.72 USD
Jan 1, 2019
-114.90 USD
Jan 1, 2020
-94.25 USD
Jan 1, 2021
0.89 USD
Jan 1, 2022
-64.23 USD
Jan 1, 2023
-95.49 USD
Jan 1, 2024
-136.72 USD
The Clearside Biomedical ROA history
YEARROAYoY
-136.72 %+43.17%
-95.49 %+48.67%
-64.23 %-7,351.23%
0.89 %-100.94%
-94.25 %-17.97%
-114.90 %-38.79%
-187.72 %+28.87%
-145.67 %+377.35%
-30.52 %-63.57%
-83.76 %-15.34%
-98.93 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Clearside Biomedical Stock analysis

What does Clearside Biomedical do? Clearside Biomedical, Inc. generates revenue through the development of drug therapies for blinding eye diseases, targeting the retina, choroid, and sclera. The company’s lead product candidate, XIPERE, is a proprietary, preservative-free suspension of the corticosteroid triamcinolone acetonide administered via suprachoroidal injection. This clinical stage biopharmaceutical firm focuses on treating conditions affecting these specific eye components to restore or preserve vision. The business model relies on advancing its proprietary therapies through clinical development rather than immediate commercial sales. By concentrating on the retina, choroid, and sclera, Clearside Biomedical, Inc. addresses critical anatomical areas involved in visual health. The company operates from its headquarters in Alpharetta, Georgia, with a dedicated team supporting its research and development efforts. Financial viability is tied to the successful progression of its drug candidates, particularly XIPERE, which utilizes a unique delivery method for triamcinolone acetonide. The firm engages in the biopharmaceutical sector by developing treatments for diseases that impact the structural and functional integrity of the eye. Its strategy centers on innovation in drug formulation and administration to treat blinding conditions effectively. Clearside Biomedical is one of the most popular companies on Eulerpool.

ROA Details

Understanding Clearside Biomedical's Return on Assets (ROA)

Clearside Biomedical's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Clearside Biomedical's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Clearside Biomedical's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Clearside Biomedical’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Clearside Biomedical stock

Return on Assets (ROA) of Clearside Biomedical is -136.72 % in 2024.

Return on Assets (ROA) of Clearside Biomedical changed from -95.49 % to -136.72 %, representing a 43.17% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) Clearside Biomedical since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s Clearside Biomedical with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Clearside Biomedical

All Key Metrics — Clearside Biomedical